Four notes:
1. Bioventus posted second quarter net sales of $109.8 million, an 89.3 percent year-over-year increase.
2. The company posted a net loss of $10.8 million, an 80.3 percent increase.
3. Revenue from its pain treatments and joint preservation business was $56.7 million, a 96.4 percent increase. Preservation and restorative therapies revenue increased 80.9 percent with $32.6 million. Bone graft substitutes revenue was $20.6 million, an 84.3 percent increase.
4. Bioventus expects to see net sales of $405 million to $415 million this year.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
